Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01106976 · ClinicalTrials.gov registry record
Imaging Biomarkers of Progression of Mobility Impairment in Parkinson Disease
A clinical trial of Parkinson's Disease, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- 67
- Enrollment target
- 1
- Study location
NCT01106976: Completed study of Parkinson's Disease, sponsored by VA Office of Research and Development.
NCT01106976 is a study of Parkinson's Disease that has completed, run by VA Office of Research and Development. The registered enrollment target is 67 participants, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01106976, a study of Parkinson's Disease, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- 67 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to evaluate changes in cholinergic brain activity over time in subjects with Parkinson disease.
Primary Outcome
AChE PMP PET hydrolysis rate outcome measure. AChE \[11C\]PMP hydrolysis rates (k3) were estimated using the striatal volume of interest (defined by manual tracing on the MRI scan of the putamen and caudate nucleus) as the tissue reference for the integral of the precursor delivery. This measure is a proxy measure for the count of cholinergic nerve terminals in the basal forebrain innervation the cortical mantle.
Conditions Studied
Study Locations (1)
Michigan
- VA Ann Arbor Healthcare System, Ann Arbor, MI - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2010-05 |
| Est. Completion | 2015-03 |
What the finished NCT01106976 record still lists
NCT01106976 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 0 interventions.
NCT01106976 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT01106976 about?
NCT01106976 is a clinical study titled "Imaging Biomarkers of Progression of Mobility Impairment in Parkinson Disease". The purpose of this research is to evaluate changes in cholinergic brain activity over time in subjects with Parkinson disease.
What is the current status of trial NCT01106976?
This trial is currently completed. The enrollment target is 67 participants. The study started on 2010-05. Estimated completion is 2015-03.
What conditions does trial NCT01106976 study?
This clinical trial studies the following conditions: Parkinson's Disease.
Who is sponsoring clinical trial NCT01106976?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01106976 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01106976's enrollment target sits among peer trials
67 70th of 158 higher than 89 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Novel DBS Stimulation Patterns for Treatment of Parkinson's Disease
RECRUITING · NA
-
rTMS to Improve Cognition in Parkinson's
RECRUITING · Phase 1
-
Deep Brain Stimulation for Visuomotor Function in Parkinson's Disease
RECRUITING
-
Ketamine for Veterans With Parkinson's Disease
RECRUITING · Phase 2
-
Feasibility and Safety of a Portable Exoskeleton to Improve Mobility in Parkinson's Disease
RECRUITING · NA
-
PET Imaging Evaluation of [11C]SY08
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia